New Zealand declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The Ledger
Page 6 of 25 of this archive, newest first.
Page 6
Japan caps liraglutide prescribing to 9 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What happens when the drug is taken away: three randomised answers
What was withdrawn, from whom, after how long, and what was measured afterwards.
What a split-sample exercise can establish, and what it cannot
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Singapore caps exenatide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Canada declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The lowest effective dose is a real concept with almost no data behind it
The commonest real-world strategy in this drug class is the least studied one.
The named comparison we promised two years ago
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Canada caps liraglutide prescribing to 5 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Same material, different gradients, different answers
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
The badge is about a sample. The listing is about a product.
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Canada caps semaglutide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Saudi Arabia caps tirzepatide prescribing to 13 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Mexico caps liraglutide prescribing to 11 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
South Korea caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Mexico declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.